Lonsurf (Trifluridine/Tipiracil HCl) Patent Expiration, LOE Window & CMS Spending
Lonsurf (Trifluridine/Tipiracil HCl) by Taiho Oncology: FDA Orange Book core substance LOE 2034-06-17 (last listed 2037-02-03), 2 AB generics, $276.8M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Taiho Oncology |
| FDA Application & Pathway | N207981 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2034-06-17 |
| Last Listed Patent or Exclusivity Date | 2037-02-03 |
| Orange Book Patents (*PED Extensions) | 7 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $276.8M |
| 2024 Medicare Part D Spend | $225.9M |
| 2024 Medicaid Spend | $50.8M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |